BioSpace News Archive

Genetown

Constellation Pharmaceuticals Announces Upcoming Presentations of Lead EZH2 and BET Clinical Programs

Constellation Pharmaceuticals today announced scientific and clinical presentations on its most advanced EZH2 and BET clinical development candidates at three upcoming conferences.

February 9, 2018

·

3 min read

BioAmber Announces Registered Direct Offering; Termination of Underwriting Agreement for Previously-Announced Public Offering

The Series A warrants have an exercise price of US$0.15 and a term of six months, exercisable upon the date of issuance.

February 9, 2018

·

8 min read

BioMidwest

Company Profile for NorthStar Medical Radioisotopes, LLC

NorthStar Medical Radioisotopes, LLC is a nuclear medicine technology company committed to providing the United States with reliable and environmentally friendly radioisotope supply solutions to meet the needs of patients and to advance clinical research.

February 9, 2018

·

1 min read

TESARO Announces U.S. FDA Approval of VARUBI IV fo

FDA

NorthStar Scores FDA Approval to Make a Medical Isotope That Hasn’t Been Produced in US in More Than 25 Years

There has been no U.S. production of Mo-99, the parent isotope of Tc-99m, for more than 25 years.

February 9, 2018

·

8 min read

Business

Novo Nordisk Files Annual Report With the SEC

Novo Nordisk has filed its Annual Report 2017 on Form 20-F for the financial year 2017 with the SEC, incorporating by reference parts of the Novo Nordisk Annual Report 2017.

February 9, 2018

·

1 min read

Drug Development

Tyme Announces Interim Phase II Safety and Efficacy Data for SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers Symposium

Tyme today announced efficacy and safety data from an ongoing Phase II trial of SM-88 in patients with non-metastatic, biochemical-recurrent prostate cancer.

February 9, 2018

·

7 min read

Policy

Elite Pharma and SunGen Pharma File ANDA

Under the terms of the Agreement, the product will be owned jointly by Elite and SunGen.

February 9, 2018

·

4 min read

Drug Development

Abeona Therapeutics Reports Top-Line Data from Phase I/II Gene Therapy Trial in MPS IIIA

Results were reported today during the WORLDSymposium for Lysosomal Diseases being held this week in San Diego, CA.

February 9, 2018

·

7 min read

Biotech Bay

Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The company granted RSUs representing an aggregate of 19,600 shares of Dermira common stock and stock options to purchase an aggregate of 254,075 shares of Dermira common stock.

February 9, 2018

·

3 min read

Biotech Bay

Relievant Announces Publication of Positive Outcomes in 12-Month SMART Sham RCT

The SMART Trial is a Level 1, randomized, sham-controlled, double-blind clinical trial for chronic low back pain whose rigor, size, and clinical outcomes are unprecedented in the field of spine care.

February 9, 2018

·

4 min read